Glenmark Pharmaceuticals has reported results for the fourth quarter (Q4FY26) and year ended 31st March, 2026

The company has reported a net loss of Rs 73.90 crore for the quarter under review as compared to net profit of Rs 147.76 crore for the same quarter in the previous year. However, total income of the company has increased by 16.99% at Rs 2,454.45 crore for Q4FY26 as compared to Rs 2,097.95 crore for the corresponding quarter previous year. On consolidated basis, the company has reported multi-fold jump in its net profit at Rs 301.41 crore for the fourth quarter ended 31st March, 2026 as compared to Rs 4.65 crore for the same quarter in the previous year. The total income of the company has increased by 21.17% at Rs 3,959.67 crore for Q4FY26 as compared to Rs 3,267.89 crore for the corresponding quarter previous year. For the year ended 31st March, 2026, the company has reported a net loss of Rs 200.80 crore as compared to net profit of Rs 1,610.35 crore for the previous year. The total income of the company has decreased by 3.87% at Rs 9,212.12 crore for year under review as compared to Rs 9,582.78 crore for year ended 31st March, 2025. For the year ended 31st March, 2026, on the consolidated basis, the company has reported 30.06% rise in its net profit at Rs 1,361.85 crore as compared to Rs 1,047.10 crore for the previous year. The total income of the company increased by 29.83% at Rs 17,443.13 crore for year under review as compared to Rs 13,435.46 crore for year ended 31st March, 2025. $GLENMARK